Welcome to our dedicated page for Orthofix Med news (Ticker: OFIX), a resource for investors and traders seeking the latest updates and insights on Orthofix Med stock.
Orthofix Medical Inc. reports developments across its orthopedic and spine medical technology portfolio. The company provides spinal implants, therapeutic solutions, limb reconstruction systems, biologics and enabling technologies, including the 7D FLASH Navigation System, for complex musculoskeletal conditions.
Recurring OFIX news includes quarterly results, guidance, product launches and commercial execution in Spine and Orthopedics. Company updates also cover pediatric limb reconstruction offerings such as FITBONE, planning software such as OrthoNext, the TRUELOK Elevate system, spine leadership realignment, distributor transitions, biologics activity and the discontinued M6 artificial disc product lines.
Orthofix (NASDAQ:OFIX) announced pediatric limb reconstruction product updates showcased at POSNA 2026 (May 6-8, 2026) in Orlando. Highlights include the newly launched FITBONE Trochanteric Intramedullary Lengthening System for femoral-lengthening with a trochanteric entry and OrthoNext 2.1 planning software enhancements.
The FITBONE Trochanteric system targets patients aged 12-21 and offers a smaller proximal diameter for greater procedural flexibility; OrthoNext 2.1 adds scheduling, automatic marker ID, 3D ring modeling and expanded deformity analysis for TL-HEX planning.
Orthofix (NASDAQ:OFIX) reported Q1 2026 net sales of $196.7M and non-GAAP pro forma net sales of $196.4M, a ~2.7% pro forma constant-currency increase versus Q1 2025. Reported net loss was $(20.9)M and non-GAAP pro forma adjusted EBITDA was $9.7M. Cash totaled $120.9M. The company reaffirmed full-year 2026 guidance: net sales $850–$860M, non-GAAP adjusted EBITDA $95–$98M, and positive free cash flow expected.
Orthofix (NASDAQ:OFIX) will release first quarter 2026 financial results on Tuesday, May 5, 2026 before market open. The company will host a conference call and webcast at 8:30 am Eastern Time the same day to review results.
Dial-in numbers: (888) 596-4144 (U.S.) or (646) 968-2525 (international); conference ID 7578740. A live webcast and the press release will be available at ir.Orthofix.com. Orthofix encourages investors to consult its Investors website for updates.
Orthofix (NASDAQ:OFIX) realigned Spine leadership, eliminating the President, Global Spine Solutions role and placing key Spine leaders to report directly to CEO Massimo Calafiore to speed decision-making and commercialization of the 7D navigation platform.
Preliminary Q1 2026 net sales were $196.7M (reported) and pro forma net sales were $196.4M, up 0.4% reported and 3% non-GAAP pro forma constant currency versus Q1 2025. 2026 guidance reaffirmed: $850M–$860M net sales, non-GAAP adjusted EBITDA $95M–$98M, ~+70 bps margin expansion at midpoint, and positive free cash flow excluding potential legal settlements.
Orthofix (NASDAQ:OFIX) reported fourth-quarter 2025 net sales of $219.9M and pro forma net sales of $218.6M, up 2.0% reported and 3.1% pro forma constant currency versus Q4 2024. Full-year 2025 reported net sales were $822.3M with pro forma net sales of $811.9M.
Full-year 2025 non-GAAP pro forma adjusted EBITDA was $85.9M (10.6% margin), full-year net loss was $(92.2M), and cash totaled $85.1M at year-end. 2026 guidance: net sales $850M–$860M, non-GAAP adjusted EBITDA $95M–$98M, and positive free cash flow (excl. potential legal settlements).
Orthofix (NASDAQ:OFIX) said CEO Massimo Calafiore and CFO Julie Andrews will present at two investor conferences in early March 2026: Canaccord Genuity Musculoskeletal Conference on March 2 at 9:30 am CT and TD Cowen Health Care Conference on March 3 at 11:10 am ET.
According to the company, live and archived webcasts will be available in the Events & Presentations section of the Orthofix investor website.
Orthofix (NASDAQ:OFIX) will release fourth quarter and full-year 2025 financial results on February 24, 2026 before market open. A conference call and webcast to review results will be held at 8:30 am Eastern Time the same day.
Dial-in numbers: U.S. (888) 596-4144; international (646) 968-2525; conference ID 2236604. The webcast and a copy of the release will be available at ir.Orthofix.com. Investors are encouraged to consult the Investors section at www.orthofix.com for updates.
Summary not available.
Orthofix (NASDAQ:OFIX) said President & CEO Massimo Calafiore and CFO Julie Andrews will participate in investor conferences in November 2025: UBS Global Healthcare Conference in Palm Beach Gardens, FL on Nov 11, 2025 at 1:15 PM ET; Stifel Healthcare Conference in New York on Nov 12, 2025 at 10:00 AM ET; and Jefferies Global Healthcare Conference in London on Nov 18–19, 2025 for 1x1 meetings.
Investors can access live and archived webcasts in the Events & Presentations section of Orthofix Investor Relations at ir.orthofix.com. The company also posts updates in the Investors section of orthofix.com.
Orthofix (NASDAQ:OFIX) will release third quarter 2025 financial results on Tuesday, November 4, 2025 before market open.
The company will host a conference call and webcast to review results on November 4, 2025 at 8:30 AM Eastern Time. U.S. dial-in is (888) 596-4144; international dial-in is (646) 968-2525; conference ID 5112586. A webcast and the press release will be available at ir.Orthofix.com.
Orthofix notes it posts investor updates in the Investors section of its website and encourages investors to check www.orthofix.com for official information.